2022 Q4 Form 10-Q Financial Statement

#000162828022027479 Filed on November 01, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $18.82M $18.98M
YoY Change 22.19% 31.72%
Cost Of Revenue $4.160M $6.506M
YoY Change -18.03% 17.06%
Gross Profit $14.66M $12.47M
YoY Change 41.95% 40.93%
Gross Profit Margin 77.89% 65.72%
Selling, General & Admin $24.14M $24.95M
YoY Change -3.79% -36.45%
% of Gross Profit 164.67% 200.05%
Research & Development $33.03M $29.14M
YoY Change 19.62% 15.05%
% of Gross Profit 225.36% 233.63%
Depreciation & Amortization $92.00K $105.0K
YoY Change -39.87% -31.37%
% of Gross Profit 0.63% 0.84%
Operating Expenses $57.17M $60.60M
YoY Change 8.48% -13.61%
Operating Profit -$42.51M -$41.62M
YoY Change 0.32% -25.33%
Interest Expense -$13.43M $14.15M
YoY Change -0.01% 3.65%
% of Operating Profit
Other Income/Expense, Net $455.0K $659.0K
YoY Change -88.45% 4969.23%
Pretax Income -$55.49M -$55.12M
YoY Change -14.79% -20.56%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$55.49M -$55.12M
YoY Change -14.79% -20.56%
Net Earnings / Revenue -294.86% -290.4%
Basic Earnings Per Share -$0.81
Diluted Earnings Per Share -$0.75 -$0.81
COMMON SHARES
Basic Shares Outstanding 73.68M shares 66.55M shares
Diluted Shares Outstanding 67.81M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $166.9M $189.3M
YoY Change -35.66% 82.63%
Cash & Equivalents $124.8M $159.4M
Short-Term Investments $42.09M $29.94M
Other Short-Term Assets $10.89M $11.41M
YoY Change -11.53% 0.85%
Inventory $35.20M $29.55M
Prepaid Expenses
Receivables $33.73M $31.49M
Other Receivables $0.00 $0.00
Total Short-Term Assets $246.7M $261.8M
YoY Change -25.01% 53.39%
LONG-TERM ASSETS
Property, Plant & Equipment $164.0K $256.0K
YoY Change -75.3% -68.67%
Goodwill
YoY Change
Intangibles $56.00K
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $0.00 $50.00M
YoY Change -100.0% 0.0%
Total Long-Term Assets $1.256M $51.04M
YoY Change -97.61% -6.5%
TOTAL ASSETS
Total Short-Term Assets $246.7M $261.8M
Total Long-Term Assets $1.256M $51.04M
Total Assets $247.9M $312.8M
YoY Change -35.02% 38.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $23.04M $18.58M
YoY Change 31.21% -10.44%
Accrued Expenses $41.00M $40.08M
YoY Change 5.63% -1.33%
Deferred Revenue $3.507M $4.045M
YoY Change -38.29% 31.84%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $92.31M $82.35M
YoY Change 25.84% 4.92%
LONG-TERM LIABILITIES
Long-Term Debt $259.9M $259.5M
YoY Change 0.63% -4.78%
Other Long-Term Liabilities $219.5M $265.1M
YoY Change 20450.0%
Total Long-Term Liabilities $479.4M $524.6M
YoY Change 40565.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $92.31M $82.35M
Total Long-Term Liabilities $479.4M $524.6M
Total Liabilities $571.7M $606.9M
YoY Change -1.18% 3.23%
SHAREHOLDERS EQUITY
Retained Earnings -$1.340B -$1.285B
YoY Change 21.12% 23.37%
Common Stock $75.00K $72.00K
YoY Change 22.95% 166.67%
Preferred Stock
YoY Change
Treasury Stock (at cost) $55.00M $55.00M
YoY Change 0.0% 0.0%
Treasury Stock Shares 1.994M shares 1.994M shares
Shareholders Equity -$323.8M -$294.1M
YoY Change
Total Liabilities & Shareholders Equity $247.9M $312.8M
YoY Change -35.02% 38.88%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$55.49M -$55.12M
YoY Change -14.79% -20.56%
Depreciation, Depletion And Amortization $92.00K $105.0K
YoY Change -39.87% -31.37%
Cash From Operating Activities -$42.47M -$42.83M
YoY Change -26.4% -38.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$11.79M $33.00M
YoY Change -76.64%
Cash From Investing Activities -$11.79M $33.00M
YoY Change -76.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.36M 46.29M
YoY Change -114.23% 1166.54%
NET CHANGE
Cash From Operating Activities -42.47M -42.83M
Cash From Investing Activities -11.79M 33.00M
Cash From Financing Activities -30.36M 46.29M
Net Change In Cash -84.62M 36.46M
YoY Change -180.43% -155.65%
FREE CASH FLOW
Cash From Operating Activities -$42.47M -$42.83M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001434868
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35986
dei Entity Registrant Name
EntityRegistrantName
Esperion Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1870780
dei Entity Address Address Line1
EntityAddressAddressLine1
3891 Ranchero Drive, Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
Ann Arbor
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48108
dei City Area Code
CityAreaCode
734
dei Local Phone Number
LocalPhoneNumber
887-3903
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ESPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73683572 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159399000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
208892000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
29942000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
50441000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31489000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22934000 usd
CY2022Q3 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
2199000 usd
CY2021Q4 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
1138000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
29545000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
34394000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9211000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11173000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
261785000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
328972000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
664000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
730000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1898000 usd
CY2022Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
56000 usd
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
56000 usd
CY2022Q3 us-gaap Assets
Assets
312827000 usd
CY2021Q4 us-gaap Assets
Assets
381590000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
18580000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17559000 usd
CY2022Q3 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
3996000 usd
CY2021Q4 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
7013000 usd
CY2022Q3 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
35395000 usd
CY2021Q4 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
30410000 usd
CY2022Q3 espr Revenue Interest Liability Current
RevenueInterestLiabilityCurrent
19636000 usd
CY2021Q4 espr Revenue Interest Liability Current
RevenueInterestLiabilityCurrent
11295000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4045000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5683000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
693000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1392000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
82345000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
73352000 usd
CY2022Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
259487000 usd
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
258280000 usd
CY2022Q3 espr Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
265048000 usd
CY2021Q4 espr Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
245744000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
524000 usd
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
634000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
606927000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
578534000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73739320 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62873694 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
72000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
61000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1045468000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
964401000 usd
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1994198 shares
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
1994198 shares
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
54998000 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
54998000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-93000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-31000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1284549000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1106377000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-294100000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-196944000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
312827000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
381590000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18980000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14409000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56657000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
63046000 usd
CY2022Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
6506000 usd
CY2021Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
5558000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
22807000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
9142000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
29143000 usd
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
25331000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
85894000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
78359000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24954000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
39265000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
84944000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
146647000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
60603000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
70154000 usd
us-gaap Operating Expenses
OperatingExpenses
193645000 usd
us-gaap Operating Expenses
OperatingExpenses
234148000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-41623000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-55745000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-136988000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-171102000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
14153000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
13654000 usd
us-gaap Interest Expense
InterestExpense
42481000 usd
us-gaap Interest Expense
InterestExpense
32923000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
659000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1297000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
36000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-55117000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-69386000 usd
us-gaap Net Income Loss
NetIncomeLoss
-178172000 usd
us-gaap Net Income Loss
NetIncomeLoss
-203989000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.62
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.78
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67806292 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67806292 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26455209 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26455209 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64021248 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64021248 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26225730 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26225730 shares
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
204000 usd
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-62000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54913000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69386000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-178234000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-203989000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-96134000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2668000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1183000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5751000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-90935000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-269394000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
168000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8584000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43668000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-304310000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4207000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
375000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
912000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5497000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-69386000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-362705000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-196944000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
431000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4436000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-232000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-56731000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-249040000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3527000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20173000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-34000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-66324000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-291698000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
301000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3537000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48673000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
204000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-55117000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-294100000 usd
us-gaap Net Income Loss
NetIncomeLoss
-178172000 usd
us-gaap Net Income Loss
NetIncomeLoss
-203989000 usd
us-gaap Depreciation
Depreciation
408000 usd
us-gaap Depreciation
Depreciation
459000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-539000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1207000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1214000 usd
espr Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
33323000 usd
espr Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
23310000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
11500000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
19832000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8555000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9322000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-901000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1096000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2272000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2251000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4849000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17836000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1129000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-30833000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2788000 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
7715000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132355000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-206103000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
18102000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
38000000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19898000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
espr Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
0 usd
espr Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
49917000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3211000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
68861000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4388000 usd
espr Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
5678000 usd
espr Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
2263000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
219000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
440000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62964000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54813000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49493000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-151290000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
258892000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
304962000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
209399000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
153672000 usd
espr Common Stock Issuance Costs Incurred
CommonStockIssuanceCostsIncurred
15000 usd
espr Common Stock Issuance Costs Incurred
CommonStockIssuanceCostsIncurred
181000 usd
espr Non Cash Right Of Use Asset
NonCashRightOfUseAsset
8000 usd
espr Non Cash Right Of Use Asset
NonCashRightOfUseAsset
10000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
50000000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
179192000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2022, thirteen customers accounted for all of the Company's net trade receivables and as of December 31, 2021, nine customers accounted for all the Company's net trade receivables.</span></div>
espr Number Of Sources Of Revenue
NumberOfSourcesOfRevenue
2 revenue_source
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
24785000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
31850000 usd
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2874000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
663000 usd
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1886000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1881000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
29545000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
34394000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
179285000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
93000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
239606000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
239575000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2021Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q3 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
200000 usd
espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0 usd
CY2022Q3 espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0 usd
CY2021Q3 espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0 usd
espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0 usd
CY2020Q4 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
46000000 usd
CY2020Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
55000000 usd
CY2020Q4 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
46000000 usd
CY2020Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
55000000 usd
CY2020Q4 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
1994198 shares
us-gaap Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
71174 shares
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8512000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8809000 usd
CY2022Q3 espr Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
20525000 usd
CY2021Q4 espr Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
16192000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2344000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3917000 usd
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3975000 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1325000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000 usd
CY2022Q3 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
35395000 usd
CY2021Q4 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
30410000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3214537 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.38
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M4D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1255600 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
685182 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
33.01
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3784955 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M4D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2098000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3784955 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
28.20
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y2M4D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2098000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2421198 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
38.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y10M28D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
163000 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.00
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.00
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
36964286 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.00
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
61900000 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
36964286 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
36964286 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
51380538 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13098695 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159399000 usd
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103672000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
208892000 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
304962000 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
50000000 usd
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
50000000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
50000000 usd
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
209399000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
153672000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
258892000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
304962000 usd

Files In Submission

Name View Source Status
0001628280-22-027479-index-headers.html Edgar Link pending
0001628280-22-027479-index.html Edgar Link pending
0001628280-22-027479.txt Edgar Link pending
0001628280-22-027479-xbrl.zip Edgar Link pending
espr-20220930.htm Edgar Link pending
espr-20220930.xsd Edgar Link pending
espr-ex311x09302022.htm Edgar Link pending
espr-ex312x09302022.htm Edgar Link pending
espr-ex321x09302022.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
espr-20220930_cal.xml Edgar Link unprocessable
espr-20220930_def.xml Edgar Link unprocessable
espr-20220930_pre.xml Edgar Link unprocessable
espr-20220930_lab.xml Edgar Link unprocessable
espr-20220930_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable